Endra Life Sciences Inc. has entered into a First Amendment to its previously announced Agreement and Plan of Merger with ASP Isotopes Inc. and its subsidiaries, Noble Africa LLC and Renergen Limited. The amendment, dated October 1, 2026, modifies several terms of the agreement governing the proposed merger.
The amended agreement removes the requirement that the board of directors of the combined company be classified into three separate classes immediately following the closing. It also replaces the form of Endra’s certificate of incorporation to eliminate classified board provisions and other provisions requiring a supermajority vote for approval.
The minimum cash closing condition has been revised to a requirement of $3,800,002.59, less certain agreed-upon expenses for investor relations activities. Additionally, the agreement contemplates a sixth addendum to the ASPI Term Loan Facility, which would increase Renergen’s borrowing capacity from ASPI from $120 million to up to $200 million.
Separately, Endra has amended the Pre-Funded Common Stock Purchase Warrant and Common Stock Purchase Warrant issued to LHE LNG Holdings, an affiliate of ASP Isotopes. These amendments remove a 4.99% beneficial ownership limitation on the affiliate’s ability to exercise the warrants.
